<DOC>
	<DOCNO>NCT01933880</DOCNO>
	<brief_summary>The purpose long term post-marketing study evaluate effectiveness safety osmotic release oral system methylphenidate hydrochloride ( OROS-MPH ) participant Attention Deficit Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>A Long Term Post-Marketing Study EffIcacy Safety Osmotic Release Oral System ( OROS ) Methylphenidate Cognitive Functions Attention Deficit Hyperactivity Disorder ( ADHD ) Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , prospective ( study follow participant forward time ) , self-controlled , long-term post-marketing study participant ADHD . The study consist 3 period : screening period , wash-out period/run-in period ( 3 day ) , open-label treatment period ( 12 week ) divide 2 period dosage adjustment period dose-optimization period . The total duration study 12 week . During dosage adjustment period , dose methylphenidate hydrochloride adjust optimal dose within 1-3 week start initial dosage 18 milligram per day ( mg/d ) increase 36 mg/d maximum dosage 54 mg/d accord therapeutic effect tolerance maintain 36 mg re-adjusted 18 mg due intolerance . Participants receive optimal dose determine dose adjustment period 9 week dose-optimization period . In study , 2 type participant enrol 2 group ( accord condition ) : OROS-MPH group ( participant ADHD ) normal child group ( healthy participant ) . The efficacy assess primarily Digit Span Test Inattention /Over activity With Aggression ( IOWA ) Conners evaluation scale . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>ADHD child must sign consent form person , parent guardian must endorse , consent form , participation child designate research program Through personal interaction assessment questionnaire , examine determine compliance DSMIV ADHD diagnostic criterion According judgment researcher , ADHD child normal intelligence . Normal intelligence define obvious evidence mental retardation general ( specific learn disability consider mental retardation general ) , formal IQ test conduct 85 mark ought score ADHD child subject psychotropic drug treatment within 6 month . Those ADHD child methylphenidate immediaterelease tablet treatment effective ( maximum daily dosage 60 mg ) , may admit Normal child IQ great equal 85 Unable fully comply cognitive function test laboratory Known allergic methylphenidate Consumption psychoactive drug currently past 30 day , include use monoamine oxidase inhibitor , clonidine , alpha 2 adrenergic receptor agonist , tricyclic antidepressant , theophylline , bishydroxycoumarin etc History alcohol , drug substance abuse Have medical history type I II bipolar affective disorder , anxiety disorder , schizophrenia pervasive developmental disorder</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Methylphenidate Hydrochloride</keyword>
	<keyword>CONCERTA</keyword>
</DOC>